Losing 3 Stone on Mounjaro: Is It Realistic?

What does the trial data say about losing this much weight?

The SURMOUNT-1 study (published in the New England Journal of Medicine) followed over 2,500 adults with obesity across 72 weeks. At the 15 mg dose, average body-weight reduction landed at around 20–21%, with some participants losing considerably more. For context, a person starting at 210 lb (15 stone) who lost 20% would shed roughly 3 stone. The numbers are real, and tirzepatide's trial record is among the strongest of any licensed weight-management medicine.

There is an important caveat. "Average" means half the participants lost less. Factors that shaped individual outcomes in the trial included baseline BMI, whether participants had type 2 diabetes (those without tended to lose more), the dose eventually reached, and how consistently the lifestyle programme was followed. Losing 3 stone is a plausible target for many people; it is not the floor or the ceiling.

A head-to-head comparison in the SURMOUNT-5 trial (72 weeks, published 2025) found that tirzepatide produced greater average weight reduction than semaglutide 2.4 mg, a useful data point if you are deciding between the two available injectable options. You can read more about how Mounjaro works and what sets it apart from other treatments.

Why does the dose you reach matter so much for the total you lose?

Mounjaro is titrated, you start at 2.5 mg because the first pen's job is settling your system, not producing its full therapeutic effect. From there, the prescriber steps the dose upward roughly every four weeks, through 5, 7.5, 10, 12.5 and up to 15 mg. The tolerability-related side effects (mainly nausea and digestive changes) are most noticeable after each step up, and most people find they settle within a week or two.

The dose you are taking when treatment stabilises has a direct relationship to the appetite suppression and calorie reduction you experience day to day. People who tolerate the higher doses and stay on them tend to see greater total loss. People who need to hold at a mid-range dose (for comfort or on prescriber advice) often still lose meaningful weight, just sometimes less than the headline 20% figure. The journey to losing 2 stone can be a milestone en route to more, or a very worthwhile outcome in its own right.

What helps tolerability: eating slower, smaller portions; avoiding very fatty meals after a dose; keeping well hydrated. These are also the habits that amplify the weight-loss effect itself. Biology and behaviour work together here.

Does hitting 3 stone depend on anything other than the medicine?

Yes. Mounjaro reduces hunger signals powerfully, but it does not override what you eat entirely. Clinical trial participants followed a reduced-calorie diet and increased their physical activity alongside treatment. NHS England's guidance on weight-management injections is explicit about wraparound lifestyle support being part of effective treatment.

Three things consistently distinguish higher-end outcomes: adequate protein (which helps preserve muscle mass while fat is lost), regular resistance or weight-bearing activity, and sustained treatment. People who pause or stop treatment before reaching a stable weight (sometimes because a pharmacy runs out, sometimes because the cost becomes difficult) tend to see some regain. Planning ahead matters. If you are thinking about what a realistic timeline looks like for a smaller initial target, the page on losing one stone on Mounjaro walks through the maths in detail.

One question our prescribers hear regularly is about the month-by-month pace. The first four weeks, on the starter dose, often produce modest but noticeable loss as appetite begins to fall. Faster reduction tends to come at the intermediate and higher doses. The page on losing a stone in a single month addresses how realistic that pace is at different points in treatment. A cost comparison is also worth looking at early on, see the Mounjaro price comparison for a grounded breakdown of what private treatment actually costs in the UK.

What if the weight loss is slower than expected, or stalls?

A plateau is common and does not mean treatment has failed. The body adapts to a lower intake over time, and there can be periods where the scales barely move even when fat is still being lost and measurements are changing. If you have been on treatment for several weeks and the scale genuinely hasn't shifted, it is worth reading about the reasons weight loss can stall on Mounjaro before drawing conclusions.

Sometimes a stall reflects being at a sub-optimal dose and simply needs the next titration step. Sometimes it reflects dietary patterns that crept back in. And occasionally it reflects a medical factor the prescriber should know about. The key is not to self-adjust the dose or stop without speaking to a clinician first. At nume, a real prescriber (not a chatbot) reviews your progress at each repeat order. That conversation is where a stall gets investigated, not ignored.

It is also worth noting that Mounjaro carries a Black Triangle (▼) designation, meaning it is under additional MHRA monitoring as a newer medicine. Reporting any unexpected side effects through the Yellow Card scheme contributes to the ongoing safety picture for everyone taking it. If you want to explore whether treatment through a clinically supervised service could be the right next step, you can start a free consultation with our prescribers today.